Wan Nam
Yonsei University · 生化学・遺伝学・分子生物学
研究室紹介
Professor Wan Nam's research lab specializes in translational drug discovery, focusing on identifying novel small-molecule therapeutics for metabolic and neurological disorders. The lab leverages innovative technologies such as DNA-encoded library (DEL) screening and cell-based assays to discover high-affinity ligands and functional agonists targeting key receptors like GLP-1R. Current research directions include the development of orally available small-molecule drugs for type 2 diabetes and obesity, as well as identifying novel inhibitors for vestibular schwannoma (VS) with reduced toxicity. The lab integrates structural biology, functional pharmacology, and high-throughput screening to accelerate the discovery of targeted therapies.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
2The glucagon-like peptide-1 receptor (GLP-1R) is a validated therapeutic target for type 2 diabetes and obesity, yet discovery of orally available small-molecule agonists remains challenging. Here, we applied DNA-encoded library (DEL) technology to identify novel small-molecule binders and functional agonists of GLP-1R. Screening of DEL against recombinant GLP-1R revealed recurring structural motifs, particularly a chromane-containing building block. Selected high-scoring off-DNA compounds were
Objectives : Our knowledge of the molecular biology of vestibular schwannomas (VS) and the development of novel medical therapies for their treatment are increasing. Although several anticancer drugs have been tested in VS, new medical therapies without toxicity are needed. Therefore, we investigated to identify novel hit compounds for potential inhibitors of VS growth using a cell-based screening assay. Method : HEI-193 cells and Nf2 knockout SC4 cells were used to investigate the inhibitory ef